Ursodeoxycholic acid did not appear to improve maternal or fetal outcomes among patients with intrahepatic cholestasis of ...

Please provide your email address to receive an email when new articles are posted on . AMSTERDAM — Bezafibrate induced an additional biochemical response in patients with primary biliary cholangitis, ...

Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "UDCA Market Size, Forecast, and Drug Insight - 2032" report has been added to ResearchAndMarkets.com's offering. This report encapsulates crucial data ...

Although UDCA was reported to improve liver enzyme levels in patients with PSC, the clinical benefits with respect to its effect on liver histology, symptoms, and radiologic appearance were not as ...

In vitro, treatment with UDCA significantly decreased C. diff spore germination, growth and toxin activity. In the mouse model, pre-treatment with UDCA had some effect on bacterial growth, but the ...

The approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in management of the condition, substantially reducing the risk of liver ...

Ursodeoxycholic acid (UDCA) is the standard first-line therapy for primary biliary cholangitis. In this large retrospective cohort study of primary biliary cholangitis patients, UDCA treatment was ...

Daewoong Pharmaceutical announced on the 17th that it has published the 3rd edition of 'Uruza Latest Insights.' This revised edition comprehensively compiles global clinical data and papers related to ...

S ince there’s no cure for primary biliary cholangitis (PBC), the main treatment goal is to slow disease progression and ease symptoms, such as itching. The good news is that, for most people, the ...